Physician profile
Chloe Schott
NPI 1447981188
$2,270.42
in general payments reported to CMS, 2019-2025
28 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.90 · 2022: $210 · 2023: $989 · 2024: $817 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.65 | 2022-2025 | |
| Lilly USA, LLC | $236.96 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $168.23 | 2021-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $121.84 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $97.16 | 2023-2024 | Auvelity |
| Astellas Pharma US INC | $96.87 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $88.63 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $71.61 | 2023-2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $63.71 | 2024-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $58.81 | 2023-2024 | Spravato, Xarelto |
| Vital Connect, INC | $58.64 | 2023-2024 | Vitalpatch Rtm |
| Phathom Pharmaceuticals, INC. | $55.09 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $53.82 | 2023-2025 | Trintellix, Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.43 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $41.12 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.29 | 2022-2023 | Vaxneuvance, Gardasil 9 |
| Tris Pharma INC | $32.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.88 | 2023-2024 | Trulance, Xifaxan |
| Pfizer INC. | $29.58 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $28.40 | 2022-2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $23.62 | 2024 | Gvoke Hypopen |
| Vivus LLC | $22.28 | 2024 | Pancreaze |
| Supernus Pharmaceuticals, INC. | $17.73 | 2022 | |
| Noven Therapeutics, LLC | $17.03 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $15.59 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $14.83 | 2022 | |
| Corcept Therapeutics | $13.43 | 2024 | Korlym |
| Currax Pharmaceuticals LLC | $13.22 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Schott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.